Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies

Haitao Wang; Gurbakhash Kaur; Alexander I. Sankin; Fuxiang Chen; Fangxia Guan; Xingxing Zang

doi:10.1186/s13045-019-0746-1

journal article Open Access Jun 11, 2019

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies

Haitao Wang

Gurbakhash Kaur

Alexander I. Sankin Fuxiang Chen Fangxia Guan Xingxing Zang

Journal of Hematology & Oncology Vol. 12 No. 1 · Springer Science and Business Media LLC

View at Publisher Save 10.1186/s13045-019-0746-1

Topics

No keywords indexed for this article. Browse by subject →

References

176

[1]

Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature. 2014;505:327–34. 10.1038/nature12984

[2]

Orkin SH, Zon LI. Hematopoiesis: an evolving paradigm for stem cell biology. Cell. 2008;132:631–44. 10.1016/j.cell.2008.01.025

[3]

Cancer statistics, 2019

Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal

CA: A Cancer Journal for Clinicians 2019 10.3322/caac.21551

[4]

Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nature Medicine. 2011;17:1086–93. 10.1038/nm.2415

[5]

Lafferty KJ, Gill RG. The maintenance of self-tolerance. Immunology and Cell Biology. 1993;71:209–14. 10.1038/icb.1993.23

[6]

Janakiram M, Chinai JM, Fineberg S, Fiser A, Montagna C, Medavarapu R, et al. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Clinical cancer research. 2015;21:2359–66. 10.1158/1078-0432.ccr-14-1495

[7]

Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734–6. 10.1126/science.271.5256.1734

[8]

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine. 2010;363:711–23. 10.1056/nejmoa1003466

[9]

Zang XX. 2018 Nobel Prize in medicine awarded to cancer immunotherapy: immune checkpoint blockade-A personal account. Genes & Diseases. 2018;5:302–3. 10.1016/j.gendis.2018.10.003

[10]

Le Dieu R, Taussig DC, Ramsay AG, Mitter R, Miraki-Moud F, Fatah R, et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood. 2009;114:3909–16. 10.1182/blood-2009-02-206946

[11]

Pistillo MP, Tazzari PL, Palmisano GL, Pierri I, Bolognesi A, Ferlito F, et al. CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood. 2003;101:202–9. 10.1182/blood-2002-06-1668

[12]

Laurent S, Palmisano GL, Martelli AM, Kato T, Tazzari PL, Pierri I, et al. CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis. British Journal of Haematology. 2007;136:597–608. 10.1111/j.1365-2141.2006.06472.x

[13]

Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng QR, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28:1280–8. 10.1038/leu.2013.355

[14]

LaBelle JL, Hanke CA, Blazar BR, Truitt RL. Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1(+), but not B7-2(+), marine myelogenous leukemia. Blood. 2002;99:2146–53. 10.1182/blood.v99.6.2146

[15]

Saudemont A, Quesnel B. In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. Blood. 2004;104:2124–33. 10.1182/blood-2004-01-0064

[16]

Huurman VAL, Unger WWJ, Koeleman BPC, Oaks MK, Chandraker AK, Terpstra OT, et al. Differential inhibition of autoreactive memory- and alloreactive naive T cell responses by soluble cytotoxic T lymphocyte antigen 4 (sCTLA4), CTLA4Ig and LEA29Y. Clinical and Experimental Immunology. 2007;150:487–93. 10.1111/j.1365-2249.2007.03513.x

[17]

Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood. 2004;103:1755–62. 10.1182/blood-2003-07-2594

[18]

Motta M, Rassenti L, Shelvin BJ, Lerner S, Kipps TJ, Keating MJ, et al. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia. 2005;19:1788–93. 10.1038/sj.leu.2403907

[19]

Do P, Beckwith KA, Beaver L, Griffin BG, Mo XK, Jones J, et al. Leukemic cell expressed CTLA-4 suppresses T cells via down-modulation of CD80 by trans-endocytosis. Blood. 2016;128:3221. 10.1182/blood.v128.22.3221.3221

[20]

Monne M, Piras G, Palmas A, Arru L, Murineddu M, Latte G, et al. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) gene polymorphism and susceptibility to non-Hodgkin’s lymphoma. American Journal of Hematology. 2004;76:14–8. 10.1002/ajh.20045

[21]

Braga WMT, da Silva BR, de Carvalho AC, Maekawa YH, Bortoluzzo AB, Rizzatti EG, et al. FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells. Cancer Immunology Immunotherapy. 2014;63:1189–97. 10.1007/s00262-014-1589-9

[22]

Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 2009;114:1545–52. 10.1182/blood-2009-03-206672

[23]

Dail M, Yang L, Green C, Ma C, Robert A, Kadel EE, et al. Distinct patterns of PD-L1 and PD-L2 expression by tumor and non-tumor cells in patients with MM, MDS and AML. Blood. 2016;128:1340. 10.1182/blood.v128.22.1340.1340

[24]

Liakou CI, Kamat A, Tang DN, Chen H, Sun JJ, Troncoso P, et al. CTLA-4 blockade increases IFN gamma-producing CD4(+)ICOS(hi) cells to shift the ratio of effector to regulatory T cells in cancer patients. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:14987–92. 10.1073/pnas.0806075105

[25]

Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019;125:1470–81. 10.1002/cncr.31896

[26]

Yang SM, Huang XJ. The poorer-risk AML, the weaker immunologic surveillance? Higher PD-L1 expression on non-APL AML cells is associated with poorer risk status according to cytogenetics and molecular abnormalities. Blood. 2016;128:1619. 10.1182/blood.v128.22.1619.1619

[27]

Berthon C, Driss V, Liu JZ, Kuranda K, Leleu X, Jouy N, et al. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. Cancer Immunology Immunotherapy. 2010;59:1839–49. 10.1007/s00262-010-0909-y

[28]

Daver N, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Ning J, et al. Defining the immune checkpoint landscape in patients (pts) with acute myeloid leukemia (AML). Blood. 2016;128:2900. 10.1182/blood-2016-07-724948

[29]

Schnorfeil FM, Lichtenegger FS, Emmerig K, Schlueter M, Neitz JS, Draenert R, et al. T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. Journal of Hematology & Oncology. 2015;8:93. 10.1186/s13045-015-0189-2

[30]

Mumprecht S, Schurch C, Schwaller J, Solenthaler M, Ochsenbein AF. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood. 2009;114:1528–36. 10.1182/blood-2008-09-179697

[31]

Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, et al. Ipilimumab for patients with relapse after allogeneic transplantation. New England Journal of Medicine. 2016;375:143–53. 10.1056/nejmoa1601202

[32]

Daver NG, Garcia-Manero G, Basu S, Cortes JE, Ravandi F, Kadia TM, et al. Safety, efficacy, and biomarkers of response to azacitidine (AZA) with nivolumab (Nivo) and AZA with nivo and ipilimumab (Ipi) in relapsed/refractory acute myeloid leukemia: a non-randomized, phase 2 study. Blood. 2018;132:906. 10.1182/blood-2018-99-120157

[33]

Kadia TM, Cortes JE, Ghorab A, Ravandi F, Jabbour E, Daver NG. Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients. Journal of Clinical Oncology. 2018;36:7014. 10.1200/jco.2018.36.15_suppl.7014

[34]

Zeidner JF, Vincent BG, Ivanova A, Foster MC, Coombs CC, Jamieson K, et al. Genomics reveal potential biomarkers of response to pembrolizumab after high dose cytarabine in an ongoing phase II trial in relapsed/refractory AML. Blood. 2018;132:4054. 10.1182/blood-2018-99-116608

[35]

Ravandi F, Daver N, Garcia-Manero G, Benton CB, Thompson PA, Borthakur G, et al. Phase 2 study of combination of cytarabine, idarubicin, and nivolumab for initial therapy of patients with newly diagnosed acute myeloid leukemia. Blood. 2017;130:815. 10.1182/blood.v130.suppl_1.815.815

[36]

Assi R, Kantarjian HM, Daver NG, Garcia-Manero G, Benton CB, Thompson PA, et al. Results of a phase 2, open-label study of idarubicin (I), cytarabine (A) and nivolumab (Nivo) in patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2018;132:905. 10.1182/blood-2018-99-116078

[37]

Ansell S, Armand P, Timmerman JM, Shipp MA, Bradley Garelik MB, Zhu L, et al. Nivolumab in patients (Pts) with relapsed or refractory classical Hodgkin lymphoma (R/R cHL): clinical outcomes from extended follow-up of a phase 1 study (CA209-039). Blood. 2015;126:583. 10.1182/blood.v126.23.583.583

[38]

Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. New England Journal of Medicine. 2015;372:311–9. 10.1056/nejmoa1411087

[39]

Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. Journal of clinical oncology. 2016;34:2698–704. 10.1200/jco.2015.65.9789

[40]

Ansell S, Gutierrez ME, Shipp MA, Gladstone D, Moskowitz A, Borello I, et al. A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). Blood. 2016;128:183. 10.1182/blood.v128.22.183.183

[41]

Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. Journal of Clinical Oncology. 2018;36:1428–39. 10.1200/jco.2017.76.0793

[42]

Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncology. 2016;17:1283–94. 10.1016/s1470-2045(16)30167-x

[43]

Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. Journal of Clinical Oncology. 2016;34:3733–9. 10.1200/jco.2016.67.3467

[44]

Armand P. Pembrolizumab in patients with relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL): data from the Keynote-013 and Keynote-170 studies. Blood. 2018;132:228. 10.1182/blood-2018-99-110220

[45]

Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. Journal of Clinical Oncology. 2017;35:2125–32. 10.1200/jco.2016.72.1316

[46]

Zinzani PL. Two-year follow-up of Keynote-087 Study: pembrolizumab monotherapy in relapsed/refractory classic Hodgkin lymphoma. Blood. 2018;132:2900. 10.1182/blood-2018-99-117045

[47]

Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131:1183–94. 10.1182/blood-2017-10-811224

[48]

Diefenbach C. A phase I study with an expansion cohort of the combinations of ipilimumab, nivolumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN research group (E4412: Arms G-I). Blood. 2018;132:679. 10.1182/blood-2018-07-864520

[49]

Wong E, Dawson E, Davis J, Koldej R, Ludford-Menting M, Lansdown M, et al. Nivolumab for relapsed or residual haematological malignancies after allogeneic haematopoietic stem cell transplantation (NIVALLO). Blood. 2018;132:4633. 10.1182/blood-2018-99-112310

[50]

Davids MS, Kim HT, Costello CL, Herrera AF, Locke FL, Maegawa RO, et al. A phase I/Ib study of nivolumab for relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation (alloHCT). Blood. 2018;132:705. 10.1182/blood-2018-99-117671

Showing 50 of 176 references

Cited By

177

Nanoparticles-enhanced CAR-T cell therapy: current advances and future directions

Zhan Wang, Guangyang Cheng · 2026

Biomarker Research

Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies

Yan-Ruide Li, Tyler Halladay · 2024

Journal of Biomedical Science

Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer

Jian Chen, Tianchuan Zhu · 2023

Molecular Cancer

CLEC12A plays an important role in immunomodulatory function and prognostic significance of patients with acute myeloid leukemia

Qiaoqiao Li, Chunyan Liang · 2022

Leukemia & Lymphoma

Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers

Zhifen Yang, Lingyu Li · 2021

Journal of Translational Medicine

Human T cell glycosylation and implications on immune therapy for cancer

Elien De Bousser, Leander Meuris · 2020

Human Vaccines & Immunotherapeu...

Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia

E. E. Ladikou, H. Sivaloganathan · 2020

Current Oncology Reports

Metrics

177

Citations

176

References

Details

Published: Jun 11, 2019
Vol/Issue: 12(1)
License: View

Authors

H

Haitao Wang

College of Environmental Science and Engineering, Ministry of Education Key Laboratory of Pollution Processes and Environmental Criteria, Tianjin Key Laboratory of Environmental Remediation and Pollution Control, Nankai University, Tianjin 300350, China

Cite This Article

Haitao Wang, Gurbakhash Kaur, Alexander I. Sankin, et al. (2019). Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. Journal of Hematology & Oncology, 12(1). https://doi.org/10.1186/s13045-019-0746-1

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies

You May Also Like